Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 34118198

Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Diabetes Endocrinol
Publication date
2021 Aug
First author
Subbiah V

This record carries publication-notice metadata. Review the notices below before relying on it.

Publication notices

absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Diabetes Endocrinol. 2021 Aug;9(8):473-474. doi: 10.1016/S2213-8587(21)00152-2.
    note
    Source null
    related pmid
    34126047
    relationship
    Comment in
  2. citation
    Lancet Diabetes Endocrinol. 2021 Oct;9(10):e4. doi: 10.1016/S2213-8587(21)00247-3.
    note
    Source null
    related pmid
    34534460
    relationship
    Erratum in

Authors and identifiers

  1. name
    Subbiah V
    type
    Author
  2. name
    Hu MI
    type
    Author
  3. name
    Wirth LJ
    type
    Author
  4. name
    Schuler M
    type
    Author
  5. name
    Mansfield AS
    type
    Author
  6. name
    Curigliano G
    type
    Author
  7. name
    Brose MS
    type
    Author
  8. name
    Zhu VW
    type
    Author
  9. name
    Leboulleux S
    type
    Author
  10. name
    Bowles DW
    type
    Author
  11. name
    Baik CS
    type
    Author
  12. name
    Adkins D
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Subbiah V
    type
    Author
  2. name
    Hu MI
    type
    Author
  3. name
    Wirth LJ
    type
    Author
  4. name
    Schuler M
    type
    Author
  5. name
    Mansfield AS
    type
    Author
  6. name
    Curigliano G
    type
    Author
  7. name
    Brose MS
    type
    Author
  8. name
    Zhu VW
    type
    Author
  9. name
    Leboulleux S
    type
    Author
  10. name
    Bowles DW
    type
    Author
  11. name
    Baik CS
    type
    Author
  12. name
    Adkins D
    type
    Author
bibliography ids
  1. nci-bib-c8aad8498f266b5224bf42ad
book metadata
content sha256
b027d8773da1d0272ec118d88ecf7167772c36f24503e10230b50573dd041e4f
document type
citation
dois
  1. 10.1016/S2213-8587(21)00120-0
electronic publication date
display
2021 Jun 9
precision
day
year
2021
evidence scope
bibliographic_metadata_only
id
pubmed:34118198
immutable id
pubmed:34118198@b027d8773da1d0272ec118d88ecf7167772c36f24503e10230b50573dd041e4f
journal
abbreviation
Lancet Diabetes Endocrinol
issn electronic
2213-8595
issn print
2213-8587
issue
8
name
The lancet. Diabetes & endocrinology
nlm unique id
101618821
pages
491-501
volume
9
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Diabetes Endocrinol. 2021 Aug;9(8):473-474. doi: 10.1016/S2213-8587(21)00152-2.
    note
    Source null
    related pmid
    34126047
    relationship
    Comment in
  2. citation
    Lancet Diabetes Endocrinol. 2021 Oct;9(10):e4. doi: 10.1016/S2213-8587(21)00247-3.
    note
    Source null
    related pmid
    34534460
    relationship
    Erratum in
outcomes validated
false
pmid
34118198
provenance
batch id
192b6392c165c6b06274
provider
NCBI PubMed ESummary
record sha256
948431783b06ffee16c61a701040fc56a2e06c473a98edf77bb450b12bc7d2d7
response sha256
7d81e9fb11ee99e6ad4116aecd61ba71cd6bf76f2a8f8f6d15c5c85e9c6c56b4
retrieved at
2026-09-09T23:48:02.713075+00:00
publication date
display
2021 Aug
precision
month
year
2021
publication types
  1. Clinical Trial, Phase I
  2. Clinical Trial, Phase II
  3. Journal Article
  4. Multicenter Study
  5. Research Support, N.I.H., Extramural
  6. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/34118198/
title
Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study.

Preserved source evidence · Not medical advice